Obstructive sleep apnea (OSA), a condition that affects a quarter of American adults, is strongly and independently associated with an increased risk for cardiovascular diseases and increased all-cause mortality. Effective treatment of OSA reduces the risk of cardiovascular diseases in patients with OSA. However, OSA remains frequently unrecognized and a majority of OSA patients do not adhere to standard continuous positive airway pressure therapy. Low rate of OSA recognition and poor adherence with standard therapy underscores the urgent need for novel diagnostic and therapeutic approaches to cardiovascular manifestations of OSA. Repetitive episodes of hypoxia/reoxygenation during transient cessation of breathing in OSA lead to activation of both arterial and venous peripheral endothelium, a key step in the development and progression of cardiovascular diseases. We have developed a minimally invasive technique of endothelial harvesting from a superficial forearm vein that allows safe collection and direct examination of endothelial cells without the artifact of culture conditions in OSA patients. Using freshly harvested endothelial cells, we have demonstrated directly peripheral endothelial activation in OSA patients as evidenced by increased expression of nuclear factor kappa B and nitrotyrosine formation and reduced expression of endothelial nitric oxide synthase. Repetitive hypoxia/reoxygenation, a phenomenon unique to sleep apnea, may activate the peripheral endothelium through specific pathways. The systemic nature of endothelial activation in OSA suggests the presence of circulating endogenous ligands that target and engage endothelial cells. We have identified peptide FHENWPS (Phe-His-Glu-Asn-Trp-Pro-Ser) as a specific ligand that targets and activates endothelial cells in OSA patients prior to onset of clinically evident cardiovascular diseases. This led us to hypothesize that ligand FHENWPS is associated with peripheral endothelial activation in OSA and thereby may accelerate the development and progression of cardiovascular diseases. To address this hypothesis, we are proposing: (1) To determine the presence of ligand FHENWPS in OSA patients without overt cardiovascular diseases before and after CPAP therapy (Aim 1), (2) To determine the effects of ligand FHENWPS on peripheral endothelial activation and systemic inflammation in OSA (Aim 2), and (3) To determine whether ligand FHENWPS augments peripheral endothelial activation and systemic inflammation in patients with OSA and coexistent CAD (Aim 3). Using a novel approach to characterize human vascular endothelium, the proposed studies may advance our understanding of endothelial activation in OSA and may allow (1) early identification of OSA patients who are at risk for vascular diseases and (2) provide basis for functional studies that may lead to the development of novel therapeutic strategies for preventing and/or reversing vascular risk in OSA.
Obstructive sleep apnea (OSA) affects 25% of American adults. OSA is strongly and independently associated with an increased risk for cardiovascular diseases and increased all-cause mortality. Incomplete understanding of the mechanisms that triple the risk for cardiovascular diseases in OSA precludes the development of effective preventive and therapeutic strategies for cardiovascular complications of OSA. Repetitive hypoxia during transient cessation of breathing in OSA alters function of the vascular endothelium, a key step in the development and progression of atherosclerosis and cardiovascular diseases. Using a novel approach to characterize vascular endothelium, we propose to identify specific molecules and their endothelial cell targets that promote endothelial alterations in patients with OSA. Unraveling of the signaling pathways of endothelial alterations in OSA may allow (1) early identification of OSA patients who are at risk for cardiovascular diseases, and (2) the development of novel therapeutic approaches for preventing and/or reversing cardiovascular risk in OSA.
|Manichaikul, Ani; Sun, Li; Borczuk, Alain C et al. (2017) Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc 14:628-635|
|Emin, Memet; Wang, Gang; Castagna, Francesco et al. (2016) Increased internalization of complement inhibitor CD59 may contribute to endothelial inflammation in obstructive sleep apnea. Sci Transl Med 8:320ra1|
|Castagna, F; Wang, J; Emit, M et al. (2015) 9A.09: PROTECTION AGAINST COMPLEMENT ACTIVITY IS REDUCED IN ARTERIAL HYPERTENSION. J Hypertens 33 Suppl 1:e119|
|Adams, Tessa; Wan, Elaine; Wei, Ying et al. (2015) Secondhand Smoking Is Associated With Vascular Inflammation. Chest 148:112-119|
|Padeletti, Margherita; Zacà, Valerio; Mondillo, Sergio et al. (2014) Sleep-disordered breathing increases the risk of arrhythmias. J Cardiovasc Med (Hagerstown) 15:411-6|
|Patel, Nina M; Kawut, Steven M; Jelic, Sanja et al. (2013) Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis. Eur Respir J 41:1324-30|
|Padeletti, Margherita; Caputo, Maria; Zacà, Valerio et al. (2013) Effect of bosentan on pulmonary hypertension secondary to systolic heart failure. Pharmacology 92:281-5|
|Marin, José M; Agusti, Alvar; Villar, Isabel et al. (2012) Association between treated and untreated obstructive sleep apnea and risk of hypertension. JAMA 307:2169-76|
|Lederer, David J; Jelic, Sanja; Bhattacharya, Jahar et al. (2012) Is obstructive sleep apnea a cause of idiopathic pulmonary fibrosis? Arch Pathol Lab Med 136:470; author reply 470|
|Krieger, Ana C; Green, Daniel; Cruz, Muriel T et al. (2011) Predictors of oxidative stress in heart failure patients with Cheyne-Stokes respiration. Sleep Breath 15:827-35|
Showing the most recent 10 out of 11 publications